Can Ozempic Treat Alcoholism? What the Evidence Shows

Can Ozempic treat alcoholism? The early evidence says the drug can blunt heavy drinking, yet no health regulator has approved it for that purpose. In a 26-week Danish trial published in The Lancet this spring, patients taking once-weekly semaglutide cut their heavy drinking days far more sharply than patients given a placebo, and they did it while also losing weight.

That result sits inside a larger question. Researchers now suspect a single brain pathway runs beneath cravings for alcohol, nicotine, cocaine and opioids, which would make this class of medicine a candidate against addiction broadly rather than one vice at a time.

The Copenhagen Trial That Put Numbers on It

The study came out of Mental Health Centre Copenhagen, where researchers led by Mette Kruse Klausen, MD, enrolled 108 adults with moderate to severe alcohol use disorder (AUD, a clinical diagnosis covering harmful and dependent drinking) and a body mass index of 30 or higher. Half received once-weekly semaglutide at 2.4 milligrams, the dose used in the Wegovy weight-loss product, and half received a placebo. Everyone also got standard cognitive behavioral therapy (CBT, talk therapy aimed at changing drinking habits). About 85% of the group met criteria for severe AUD, so this was not a sample of light social drinkers.

The headline figure is the drop in heavy drinking days. People on the drug cut theirs by 41.1 percentage points from baseline, against 26.4 points in the placebo arm, a treatment difference of 13.7 percentage points that cleared statistical significance. Side effects were mostly the mild to moderate nausea and gut complaints already familiar to GLP-1 users, and 88 of the 108 participants finished the full course.

This was the first double-blind, randomized, placebo-controlled test of semaglutide for drinking, and you can read the full Copenhagen semaglutide trial in The Lancet. The authors called the effect a robust signal and a reason to keep testing GLP-1 receptor agonists, while stopping well short of saying the question is settled.

Why One Drug Touches So Many Cravings

GLP-1 stands for glucagon-like peptide-1, a gut hormone the medicine mimics. The drugs were built to manage type 2 diabetes and then obesity, but the brain interest comes from where they act, not what they were designed for. Asim Shah, a professor and executive vice chair of psychiatry and behavioral sciences at Baylor College of Medicine, explained the leading theory in an interview with Gizmodo: craving runs on dopamine, and the same reward circuit lights up whether the trigger is food, a cigarette or a drink.

Whenever you crave something and you eat it or you take it, that gives you pleasure. That is the dopamine functioning in the brain. And all of this is related to the same thing, whether it’s a craving for food, craving for smoking, craving for alcohol, any drug.

That is Shah, describing why a single mechanism could explain so many results at once. The first hints were accidental. Doctors noticed that patients losing weight on these injections were also quitting cigarettes and drinking less without being asked to, which sent scientists looking for the link on purpose.

The pattern shows up in the lab too. Rodents on GLP-1 drugs drink less alcohol, press the lever for cocaine less often and show weaker interest in nicotine, findings that line up across a systematic review of GLP-1 receptor agonists in substance use disorders. Newer molecules are widening the field. Tirzepatide, a dual agonist that pairs GLP-1 with a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide), is now entering its own addiction trials. The weight-loss angle has its own active debate, and a recent comparison of surgery against GLP-1 drugs for body weight shows how much these medicines have reset expectations across medicine in general.

Beyond Alcohol: The 600,000-Patient Signal

If the Copenhagen trial is small and tightly controlled, the largest evidence so far is the opposite: huge, messy and observational. Researchers at Washington University in St. Louis mined the health records of 606,434 U.S. veterans with type 2 diabetes, tracking who developed a substance use disorder over roughly three years and who already had one. The work, published in The BMJ, is the broadest look yet at whether one drug class moves the needle on many addictions at once.

New Diagnoses Fell Across the Board

Among veterans with no prior addiction, those on GLP-1 medicines were less likely to be newly diagnosed with a substance use disorder over the study window. The size of the drop varied by substance but pointed the same direction every time.

And Existing Users Saw Fewer Crises

For veterans who already had an addiction, the harm-reduction numbers were larger still: roughly 30% fewer emergency visits, 25% fewer hospitalizations, 40% fewer overdoses and 50% fewer drug-related deaths in the GLP-1 group. Ziyad Al-Aly, MD, the senior author and a clinical epidemiologist at WashU Medicine, framed it bluntly. “GLP-1 medication is likely acting against the craving itself,” he said in the university’s writeup of the veterans database study. “It blunts that craving that pulls people toward whatever they’re addicted to.” In raw terms, that worked out to about seven fewer new diagnoses and twelve fewer serious harm events per 1,000 patients on the drugs.

What the Evidence Still Cannot Say

Shah was careful to keep the Lancet result in proportion. A hundred patients is a respectable mid-sized trial, he noted, the kind of start-up study that bigger and longer work is built on, not the final word. The veterans data, for its part, is observational, which means it can show a strong association but cannot prove the drug caused the difference.

Several questions stay open, and they are the ones that decide whether any of this reaches a clinic:

• Does the benefit hold in people who do not also have obesity, since the Copenhagen group all had a BMI of 30 or higher?
• How fast does the craving effect kick in, and how strong is it across different substances?
• Does it last after someone stops the injections, or does the urge return once the drug clears?
• Can a single course help someone fighting more than one addiction at the same time, given that the mechanism is shared?

That durability question is the big one. Drinking and weight both tend to rebound when weight-loss drugs are stopped, which is why researchers want long follow-up before calling semaglutide a treatment rather than a temporary brake. The U.S. National Institutes of Health, which is funding parallel work, has stressed the same point in its summary of GLP-1 and heavy-drinking research: the early data is encouraging, and it is still early.

Why You Cannot Get a Prescription for Drinking Yet

Here is the practical bottom line. Semaglutide is approved for type 2 diabetes and obesity, not for alcohol or any other addiction, so a doctor cannot write a prescription aimed at your drinking. Shah’s advice splits cleanly. If you already qualify for a GLP-1 because of diabetes or weight, take it, and any drop in your drinking or smoking is a welcome bonus. If you want the drug specifically to quit alcohol or cigarettes, the honest route today is a clinical trial, and more than a dozen are enrolling.

There is also a safety footnote for anyone tempted to shortcut the system. The surge in demand has produced a flood of cheap, unapproved knockoffs, and regulators are pushing back, as seen in one state effort against misleading compounded GLP-1 products. Chasing an off-label benefit through an unverified supplier carries its own risks.

None of that erases what the science is showing. Within a few years, the trials now running will say whether GLP-1 drugs become a standard tool against addiction or stay a promising lead that did not scale. For now, the most accurate answer to the question in the headline is a qualified yes that comes with a wait.

Frequently Asked Questions

Is Ozempic approved to treat alcoholism?

No. Ozempic and Wegovy, which both contain semaglutide, are approved for type 2 diabetes and obesity, not for alcohol use disorder. The drinking benefit seen in trials is an off-label effect that no regulator has cleared as a treatment.

How much did drinking actually drop in the semaglutide trial?

In the 26-week Copenhagen trial, patients on semaglutide cut their heavy drinking days by 41.1 percentage points from baseline, compared with 26.4 points on placebo, a difference of 13.7 points. They also cut total alcohol intake by about 1,550 grams per 30 days versus about 1,026 grams for placebo.

Does semaglutide work for addictions other than alcohol?

Early evidence suggests it might. A WashU analysis of 606,434 veterans linked GLP-1 use to lower rates of new cannabis, cocaine, nicotine and opioid disorders, with opioids showing the largest drop at 25%. These are associations from records, not proof from controlled trials, and dedicated studies are still underway.

How does a diabetes drug reduce cravings?

The leading theory is that GLP-1 drugs act on the brain’s dopamine reward system, the same circuit behind cravings for food, alcohol, nicotine and other drugs. By dampening that signal, the medicine appears to weaken the urge that drives addictive behavior.

Can I ask my doctor for Ozempic to help me drink less?

Not for that reason alone. Because it is not approved for addiction, doctors generally cannot prescribe it to reduce drinking. If you already qualify for a GLP-1 for diabetes or obesity, any reduction in drinking is a bonus. Otherwise, joining an enrolling clinical trial is the available path.

Does the effect last after you stop taking the drug?

That is unknown. Researchers have not yet followed patients long enough after stopping to know whether reduced drinking holds or whether cravings return once the drug clears. Answering this is a main goal of the larger trials now being planned.

Disclaimer: This article is for informational purposes only and is not medical advice. Semaglutide is not approved to treat alcohol use disorder or any other addiction, and using prescription medication off-label carries risks. Anyone considering treatment for drinking or substance use should consult a qualified healthcare professional. Figures cited are accurate as of publication.